Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.43 |
| ▸ | NQO2 | P16083 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 3/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MDM4 | O15151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3214536 | 0.81 | MTNR1A (0.58) | MTNR1AMTNR1BNQO2CYP3A4SMN1; SMN2 | |
| SCHEMBL3221402 | 0.77 | P2RX7 (0.35) | MTNR1AMTNR1BMAOB | |
| SCHEMBL8578397 | 0.62 | MTNR1A (0.63) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL30353206 | 0.62 | KDM4E (0.64) | MTNR1AMTNR1BNQO2HTT | |
| SCHEMBL21712157 | 0.61 | MTNR1A (0.52) | MTNR1AMTNR1BNQO2HTTCYP3A4 | |
| SCHEMBL3210719 | 0.61 | ALDH1A1 (0.56) | MTNR1AMTNR1BNQO2CYP3A4 | |
| SCHEMBL1563219 | 0.60 | TUBB1 (0.64) | MTNR1AMTNR1B | |
| SCHEMBL7291800 | 0.59 | NQO2 (0.50) | MTNR1AMTNR1BNQO2CYP3A4 | |
| SCHEMBL3225498 | 0.59 | MAPT (0.44) | MTNR1AMTNR1BNQO2HTTMAPK1 | |
| SCHEMBL8604971 | 0.59 | MTNR1A (0.46) | MTNR1AMTNR1BNQO2USP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063125-A1 | MELATONIN DERIVATIVES AND THEIR USE AS ANTIOXIDANTS | UNIVERSITY OF SUNDERLAND (GB) | 2010-03-11 | — | — | US | claimed |
| US-8258173-B2 | Melatonin derivatives and their use as antioxidants | UNIVERSITY OF SUNDERLAND (GB) | 2012-09-04 | — | — | US | disclosed |
| US-8258173-B2 | Melatonin derivatives and their use as antioxidants | UNIVERSITY OF SUNDERLAND (GB) | 2012-09-04 | — | — | US | disclosed |
| US-8258173-B2 | Melatonin derivatives and their use as antioxidants | UNIVERSITY OF SUNDERLAND (GB) | 2012-09-04 | — | — | US | disclosed |
| US-20100063125-A1 | MELATONIN DERIVATIVES AND THEIR USE AS ANTIOXIDANTS | UNIVERSITY OF SUNDERLAND (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063125-A1 | MELATONIN DERIVATIVES AND THEIR USE AS ANTIOXIDANTS | UNIVERSITY OF SUNDERLAND (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063125-A1 | MELATONIN DERIVATIVES AND THEIR USE AS ANTIOXIDANTS | UNIVERSITY OF SUNDERLAND (GB) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063125-A1 | MELATONIN DERIVATIVES AND THEIR USE AS ANTIOXIDANTS | MTNR1A, MTNR1B, TXNRD2 | MTNR1A 1/4885MTNR1B 2/4885NQO2 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.